

# **Heparin Diversification**

**Sheep Heparins as an Alternate for  
Porcine Heparins**

**Yiming Yao  
Ronnsi Pharma  
Feb., 2016**

- ◆ **Introduction**
- ◆ **Porcine, Ovine and Bovine Heparin Structural Difference**
- ◆ **Porcine, Ovine and Bovine Heparin Biologic Difference**
- ◆ **Conclusions**



# Heparin Usage Worldwide

- ◆ Heparin, especially LMWH, is used extensively in developed countries.
- ◆ Historic, heparin is extracted from porcine, bovine and ovine mucosa or lung.
- ◆ Since the outbreak of BSE in 1990s, porcine heparin is the sole source for US and Europe.
- ◆ Bovine is still used in South America and some Muslim countries.
- ◆ Heparin is significantly under-used in Muslim countries.
  - ◆ Lower income, lower health spending
  - ◆ Porcine source is an issue for Muslim population

# Why Need Heparin Diversification?

- ◆ **90% of porcine intestines have been used for heparin production.**
- ◆ **Single source and 70% from China**
- ◆ **Heparin usage increases as world population income grow.**
- ◆ **Muslin countries are seeking alternative heparin sources.**
- ◆ **Worldwide ovine and bovine population are significant and 80% are farmed outside of China.**

# Worldwide Livestock Population




## 2010 World Sheep Inventory - Top 10 countries

Country	Number of head
China	134,021,213
India	73,991,000
Australia	68,085,500
Iran	54,000,000
Sudan	52,014,100
Nigeria	35,519,800
New Zealand	32,562,600
United Kingdom	31,000,000
Pakistan	27,800,000
Ethiopia	25,979,900
<b>Total</b>	<b>1,078,948,201</b>


**Worldwide, there are 1.4 billion cattle, 1.9 billion sheep and goats, 980 million pigs.**

# Heparin API MW Distribution




Item	Mw(Da)	M <sub>24000</sub>	M <sub>8000-16000</sub> / M <sub>16000-24000</sub>
Specifications (EP8.0)	15,000-19,000	NMT 20%	NLT 1.0
Porcine_HS	17,685 Da	16.6 %	1.2
Ovine_HS	16,804 Da	17.2 %	1.7
Bovine intestinal mucosa_HS	16,417 Da	16.6 %	2.1
Bovine lung_HS	<b>13,588 Da</b>	8.9 %	2.7


# Disaccharide Analysis




1#  
Δ IVA




2#  
Δ IVS




3#  
Δ IIA




5#  
Δ IIIA




6#  
Δ IIS




7#  
Δ IIIS




8#  
Δ IA




9#  
1,6-Anhydro Δ I S or  
1,6-Anhydro Δ I S glucose




10#  
Δ IIA-Δ IVSglu




11#(Main peak)  
Δ I S




13#  
Δ IIA-Δ IISglu



14#  
1,6-Anhydro Δ I S- I S epi or  
1,6-Anhydro Δ I S- I S mannose





4#  
1,6-Anhydro Δ IIS or  
1,6-Anhydro Δ IIS glucose





1,6-Anhydro Δ IIS epi or  
1,6-Anhydro Δ IIS mannose

# Disaccharide Analysis







# Disaccharide Analysis




### Porcine mucosa Heparin (PMH)




### Ovine mucosa heparin (OMH)



### Bovine mucosa heparin (BMH)




### Bovine lung heparin (BLH)



# 2D-HSQC-NMR

campione G11480\_OMH  
 temperatura 298 K  
 analisi PCA  
 SR -45.32 -435.9  
 data 12/06/2015



```

Current Data Parameters
NAME      G11480_OMH
EXPNO    3
PROCNO   1

F2 - Acquisition Parameters
Date_    20150614
Time     3.46
PROBHD   5 mm CPTCI 1H-
PULPROG  zgpg30
TD       1024
SOLVENT  D2O
NS       8
DS       16
TE       298.0 K
CNS12    150.0000000
CNS17    -0.5000000
D0       0.00000300 sec
D1       2.50000000 sec
D4       0.00166667 sec
D11     0.03000000 sec
D16     0.00200000 sec
D24     0.0086207 sec
IN0     0.00004150 sec

===== CHANNEL f1 =====
SFO1     600.1328208 MHz
NUC1     1H
P1       11.12 usec
P2       22.24 usec
P22      0 usec
PLW1     7.00000000 W

===== CHANNEL f2 =====
SFO2     150.9148812 MHz
NUC2     13C
PCPD2    0 usec
P3       13.00 usec
P4       500.00 usec
P24     2000.00 usec
PCPD2    60.00 usec
PLW0     0 W
PLW2     123.0000000 W
PLW12    5.77419996 W
SFO13[3] Crp60,0.5,20.1
SFO13    0.500
SFO13F3  0 Hz
SFW2     31.76000023 W
SFO13M[7] Crp60comp,4
SFO13L7  0.500
SFO13F7  0 Hz
SFW7     31.76000023 W

----- GRADIENT CHANNEL -----
GPNAM[1] SMSQ10.100
GPNAM[2] SMSQ10.100
GPNAM[3] SMSQ10.100
GPNAM[4] SMSQ10.100
GPZ1     80.00 %
GPZ2     20.10 %
GPZ3     11.00 %
GPZ4     -5.00 %
P16     1000.00 usec
P19     600.00 usec

F1 - Acquisition parameters
TD       320
SFO1     150.9149 MHz
FIDRES   37.450404 Hz
SW       79.834 ppm
FaMODE   Echo-Antiecho

F2 - Processing parameters
SI       4096
SF       600.129547 MHz
WDW      QSINE
SSB      2
LB       0 Hz
GB       0
PC       1.40

F1 - Processing parameters
SI       1024
MZ      echo-antiecho
SF       150.9023731 MHz
WDW      QSINE
SSB      2
LB       0 Hz
GB       0
  
```


# 2D Quantitative HSQC NMR

Amines												
<i>Ronzoni code</i>	<i>Ronnsi code</i>	A1NS-(I2S)	A1NS-I	A1NS-G	A*	ANAc-G	ANAc-I	ANH2	ANSared	ANAcared	A-(GalA)+A?	A6S
G11480	RXJL-0009-SJT-108-01	69.8	6.0	8.9	6.5	4.2	0.3	0.4	1.4	1.0	1.1	86.6
G11481	RXJL-0009-SJT-105-01	68.7	5.5	10.6	6.3	4.2	0.2	0.0	1.0	1.2	1.8	84.7
G11482	RXJL-0009-SJT-108-02	67.6	5.4	10.5	6.6	5.3	0.3	0.5	1.6	0.9	0.8	85.5
<i>mean</i>		<b>68.7</b>	<b>5.7</b>	<b>10.0</b>	<b>6.5</b>	<b>4.6</b>	<b>0.3</b>	<b>0.3</b>	<b>1.3</b>	<b>1.0</b>	<b>1.2</b>	<b>85.6</b>
<b>Porcine mean</b>		59.0	8.4	9.5	6.7	12.2	0.6	1.1	0.4	0.6	1.3	77.2
Uronic acid		I2S	I-A6S	I-A6OH	G-A*	G-ANS	G-Anac	Epox	GalA	G2S		
G11480	RXJL-0009-SJT-108-01	83.2	4.8	1.2	1.5	5.5	2.4	0.4	0.4	0.6		
G11481	RXJL-0009-SJT-105-01	83.0	4.9	1.2	1.5	5.2	2.6	0.3	0.5	0.7		
G11482	RXJL-0009-SJT-108-02	83.7	4.6	1.1	1.7	5.6	2.0	0.5	0.5	0.4		
<i>mean</i>		<b>83.3</b>	<b>4.8</b>	<b>1.2</b>	<b>1.6</b>	<b>5.5</b>	<b>2.3</b>	<b>0.4</b>	<b>0.4</b>	<b>0.6</b>		
<b>Porcine mean</b>		72.3	5.6	2.9	2.4	6.7	6.3	0.3	1.2	0.0		
LR		(Gal1+G)/2 (LR)	% Ser ox			Sulf deg.						
G11480	RXJL-0009-SJT-108-01	2.8	96.1			2.71						
G11481	RXJL-0009-SJT-105-01	2.9	97.7			2.69						
G11482	RXJL-0009-SJT-108-02	2.5	94.1			2.69						
<i>mean</i>		<b>2.7</b>	<b>96.0</b>			<b>2.69</b>						
<b>Porcine mean</b>		1.3	95.0			2.42						


# Anticoagulant activity

Item	Specifications (EP8.0)	Porcine	Ovine	Bovine lung	Bovine intestinal mucosa
Batch no.	/	/	<b>RX0009-SJT-105-1</b>	RX0014-JCJ-045	RX0014-JCJ-046
Anti-Xa	NLT 180 IU/mg Calculated on a dry basis	>180	<b>181.5</b>	135.1	123.8
Anti-IIa	/	>180	<b>180.9</b>	126.2	168.7
Anti-Xa/ Anti-IIa	/	~1:1	<b>1.00</b>	1.07	0.73
Anticoagulant activity (by sheep plasma)	/	>180	<b>179</b>	152	167

# Heparins in Human Whole Blood ACT




# Whole Blood Clotting Times




At an equigravimetric level all agents produced similar effects.

# Neutralization by Protamine Sulfate







# Relative Inhibition of Factor Xa in an AT Supplemented System



# Relative Inhibition of Factor IIa in an AT Supplemented System



# Thrombin Generation Inhibition Technoclone Thrombin Generation Assay



# Conclusions

---

- 1.MW, disaccharide analysis and 1D, 2D NMR were performed for porcine, bovine and ovine purified heparin.**
  - 2.Overall ovine heparin is structurally closer to porcine. Significant difference was observed for bovine heparin in disaccharide and NMR.**
  - 3.In the whole blood supplementation studies the bovine, ovine and porcine exhibited similar anticoagulant activity as measured by ACT, APTT.**
- 
- 1.Protamine sulfate neutralization was comparable except the bovine heparins were only partially neutralized at higher concentrations.**

# Conclusions

---

- 6. The anti-Xa and anti-IIa activity of ovine and porcine heparins were comparable and were much higher than bovine heparin.**
- 6. The AT supplemented systems ovine and porcine heparins exhibited stronger inhibition of both Xa and IIa in comparison to bovine heparin.**
- 7. These studies suggest that ovine heparin is functional comparable to porcine heparin.**

# Acknowledgments

---

**Ronnsi Pharma Co. , Ltd**

**Loyola Medical School**

**Yongsheng Jin**

**Professor Jawed Fareed  
and his group**

**Xiaohua Lu**

**Ningxia Wang**

**Ronzoni Institute**

**Dr. Marco Guerrini**